S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$10.27
-0.10 (-0.96%)
(As of 06/9/2023 ET)
Compare
Today's Range
$10.09
$10.59
50-Day Range
$6.84
$10.80
52-Week Range
$4.82
$11.11
Volume
177,738 shs
Average Volume
198,948 shs
Market Capitalization
$492.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.40

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.7% Upside
$16.40 Price Target
Short Interest
Bearish
2.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

884th out of 987 stocks

Pharmaceutical Preparations Industry

440th out of 484 stocks


ALPN stock logo

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Stock News Headlines

Famous Wall Street Crash System Flashes RED
Hundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Q4 2022 Alpine Immune Sciences Inc Earnings Call
See More Headlines

ALPN Price History

ALPN Company Calendar

Last Earnings
5/11/2023
Today
6/10/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.40
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+59.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-57,760,000.00
Net Margins
-245.92%
Pretax Margin
-236.91%

Debt

Sales & Book Value

Annual Sales
$30.06 million
Book Value
$3.90 per share

Miscellaneous

Free Float
21,729,000
Market Cap
$492.65 million
Optionable
Not Optionable
Beta
1.24

Key Executives

  • Mitchell H. GoldMitchell H. Gold
    Executive Chairman & Chief Executive Officer
  • Stanford L. Peng
    President & Head-Research & Development
  • Thaedra Thullberry
    Finance Director
  • James Paul Rickey
    Chief Financial Officer, Secretary & Senior VP
  • Wayne R. Gombotz
    Chief Technology Officer













ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price forecast for 2023?

4 equities research analysts have issued 1-year price objectives for Alpine Immune Sciences' shares. Their ALPN share price forecasts range from $11.00 to $25.00. On average, they expect the company's stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2023?

Alpine Immune Sciences' stock was trading at $7.35 at the beginning of 2023. Since then, ALPN shares have increased by 39.7% and is now trading at $10.27.
View the best growth stocks for 2023 here
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Thursday, May, 11th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.09. The biotechnology company had revenue of $9.39 million for the quarter, compared to analyst estimates of $8.60 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 40.29% and a negative net margin of 245.92%.

What ETFs hold Alpine Immune Sciences' stock?

ETFs with the largest weight of Alpine Immune Sciences (NASDAQ:ALPN) stock in their portfolio include iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB).

What other stocks do shareholders of Alpine Immune Sciences own?
What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Great Point Partners LLC (7.80%), BlackRock Inc. (3.24%), BVF Inc. IL (1.79%), Geode Capital Management LLC (1.16%), State Street Corp (0.72%) and Renaissance Technologies LLC (0.69%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $10.27.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $492.65 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -